Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma
about
Polymeric micelles of suberoylanilide hydroxamic acid to enhance the anticancer potential in vitro and in vivo.Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacyCellular metabolism of tumor-associated macrophages - functional impact and consequences.The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy.Cell death-based treatment of neuroblastoma.Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy
P2860
Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 March 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma
@en
Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma.
@nl
type
label
Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma
@en
Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma.
@nl
prefLabel
Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma
@en
Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma.
@nl
P2093
P2860
P1433
P1476
Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma
@en
P2093
Gosse J Adema
Ingrid C Brok
Inna Armandari
Louis Boon
Maaike W G Looman
Martijn H den Brok
Melissa Wassink
Michiel Kroesen
Paul R Gielen
Peter M Hoogerbrugge
P2860
P304
P356
10.1080/2162402X.2016.1164919
P577
2016-03-28T00:00:00Z